Pixium Vision was a bioelectronics and brain-machine interface technology company specialized in neuromodulation application whose mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy.

Pixium was created in Paris, France in November 2011 as a spin-out of the Vision Institute and Université Pierre et Marie Curie, and based on collaborative work involving several leading academic teams across Europe. Pixium was backed by a syndicate of blue-chip European venture capital firms including Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Seventure and Polytechnos.

Pixium's first device, IRIS I (Intelligent Retinal Implantable System) was based on the IMI Retinal Implant System and entered clinical trials in 2013. A second-generation system (IRIS II) based on the same format, but offering better visual acuity and featuring several breakthrough technologies, was also under development, but later scrapped to focus on the PRIMA system.

Pixium closed business on January 31, 2024.

On April 25, 2024 it was announced that Science Corporation had acquired the IP and related assets for the PRIMA retinal implant, providing a path forward for three clinical trials in late-stage macular degeneration and the ultimate commercialization of the PRIMA implant.

Visual Prostheses

• IRIS I

  epiretinal

• IRIS II

  epiretinal

• PRIMA

  subretinal

Research Spotlights

• From Collapse to Comeback: Behind the Scenes of Pixium Vision’s Revival with Dr. Brian Burg

  April 26, 2024 8:34 AM